Clinical Applications of Bone Marrow CD34 Immunohistochemistry (BM CD34 IHC) Assay: International Council for Standardization in Hematology (ICSH) Guidelines
- 21 December 2024
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (3) , 387-397
Abstract
Introduction: Investigation of bone marrow (BM) trephine biopsies and/or clot sections by CD34 immunohistochemistry (IHC) testing has been used by pathologists for several decades, and its clinical value has been well established with QBEND10 being the most frequently used primary antibody (Ab) clone. However, most other parameters related to the IHC protocol as well as the readout vary widely between clinical laboratories and in the published literature. The ICSH Working Group having reviewed the published evidence has established guidelines that will help to harmonize performance and reporting of CD34 IHC on BM biopsies.Methods: The methodology is based on the published “guidelines for guidelines” (GRADE, AGREE) with modifications to the specific laboratory medicine environment and to specific key questions. Review of the published literature resulted in 49 articles relevant to clinical applications of the BM CD34 IHC. Five key questions were addressed including testing indications, technical performance, readout methodology, terminology, and reporting.Results: A total of 23 guidelines were grouped according to the key questions.Conclusion: BM CD34 IHC testing is complex with both the protocol and the pathologist's readout requiring validation to ensure reported results are reproducible and accurate. The readout/interpretation must be adapted to a specific purpose of the assay (clinicopathological question) and the type and overall sample quality. Standardized terminology and reporting are essential if CD34 IHC assay is being used for clinical diagnostics.Keywords
Funding Information
- Agilent Technologies
This publication has 31 references indexed in Scilit:
- Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemiaBlood Reviews, 2023
- Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classificationJournal of Hematopathology, 2020
- GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences—Risk of bias and indirectnessJournal of Clinical Epidemiology, 2019
- High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaAmerican Journal of Hematology, 2019
- GRADE guidelines: 8. Rating the quality of evidence—indirectnessJournal of Clinical Epidemiology, 2011
- GRADE guidelines 6. Rating the quality of evidence—imprecisionJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 2. Framing the question and deciding on important outcomesJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)Journal of Clinical Epidemiology, 2011